The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


BAQSIMI



Eli Lilly Nederland B.V.EU/1/19/1406/001-002

Main Information

Trade NameBAQSIMI
Active SubstancesGLUCAGON
Dosage FormNasal powder in single-dose container
Licence HolderEli Lilly Nederland B.V.
Licence NumberEU/1/19/1406/001-002

Group Information

ATC CodeH04AA Glycogenolytic hormones
H04AA01 glucagon

Status

Authorised/WithdrawnAuthorised
Licence Issued16/12/2019
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back